Isomorphic Labs raises $5 billion to advance AI drug development
Greenoaks and Sequoia Capital co-led the Series C round, with funding intended to accelerate the company's move toward clinical trials.

Alphabet's Isomorphic Labs said it raised $5 billion in Series C funding, with Greenoaks and Sequoia Capital leading the investment. Chief Executive Demis Hassabis told Bloomberg the funding would help accelerate the company's progress toward clinical trials.
The financing follows a $2.1 billion round in May. Andreessen Horowitz joined as a new investor, while Isomorphic said Alphabet made another significant investment. Every existing investor participated, and demand exceeded the amount available, the company said.
Isomorphic did not reveal a valuation, according to Bloomberg. The news service had previously reported that the financing would put its value at about $50 billion.
The company said its IsoDDE drug design engine had delivered positive preclinical results across internal cancer and immunology programs and work with partners. Hassabis said more than 20 programs were underway. Its pharmaceutical partners include Novartis, Johnson & Johnson and Eli Lilly.
Hassabis declined to update his January expectation that initial clinical trials would begin by the end of 2026. He told Bloomberg that regulatory submissions remained on track and that further announcements would come in 2027. Bloomberg noted that no AI-designed drug has received regulatory approval.
Hassabis also said the funding would support expansion beyond small-molecule medicines into other types of drugs, including large-molecule biologics. Founded in 2021 to build on Google DeepMind's AlphaFold protein structure model, Isomorphic is headquartered in London.




